Curriculum Update #4

• Bradykinin and angiotensin-(1-7): Emerging allies in vascular function

The role of endothelial function in cardiovascular health provides an important conceptual framework for development of risk reduction strategies. This slide program, part of a continuing series of educational activities, is produced under the auspices of the Vascular Biology Working Group (VBWG) and covers new aspects of the renin-angiotensin system (RAS) that have implications for vascular function.

This program discusses new data on the interaction between the RAS and the kallikrein-kinin system (KKS), as well as intriguing new research on the novel RAS peptide angiotensin-(1-7). These data extend our understanding of ACE inhibition at the tissue level and its role in reducing the risk of cardiovascular morbidity and mortality.


Advances in our understanding of the kallikrein-kinin system (KKS) and the renin-angiotensin system (RAS) have led to new insights into the mechanism of action of angiotensin-converting enzyme (ACE) inhibitors.

In particular, this Curriculum Update covers the following topics:

  • Beneficial cardiovascular effects of bradykinin
  • Receptors and pathways of the RAS and the KKS
  • Relative roles of ACE, angiotensin-(1-7), and angiotensin II (Ang II) in maintenance of blood pressure and endothelial function
  • Evidence that bradykinin is an important mediator of the cardiovascular effects of tissue ACE inhibition
  • Importance of tissue ACE inhibition in cardiovascular risk reduction

Published by Medical Education Consultants, Inc. (MEDCON), on behalf of the University of Florida College of Medicine. Supported by an unrestricted educational grant from Pfizer Inc.

©2000 MEDCON

The editorial content of this program expresses the views of the individual contributors and does not necessarily reflect the views or recommendations of the University of Florida College of Medicine, Pfizer Inc, or the publisher. The indications and dosages of drugs discussed in this program may vary from those approved by the Food and Drug Administration (FDA). The reader is advised to consult the full prescribing information for each medication prior to use.

Bradykinin and angiotensin-(1-7): Emerging allies in vascular function

Download CU4.ppt (23 slides - 1.1MB)

Bradykinin and angiotensin-(1-7): Emerging allies in vascular function Bradykinin, Ang-(1-7), and vascular health Vasculoprotective effects of bradykinin Bradykinin B2 receptor blockade decreases basal coronary tone Bradykinin B1 and B2 receptor stimulation in canine coronary circulation Cardiovascular role of bradykinin as determined by knockout mice Components and major actions of the kallikrein-kinin and renin-angiotensin systems Vasculoprotective effects of Ang-(1-7) Ang-(1-7) levels are significantly reduced in hypertension Differing effects of Ang-(1-7) and Ang II on VSMC growth Ang-(1-7) inhibits VSMC growth through activation of a non-AT1, non-AT2, D-Ala-Ang-(1-7)-sensitive receptor Ang-(1-7) receptor blockade elevates blood pressure of salt-depleted hypertensive rats ACE inhibition increases NO formation via bradykinin Effect of selective or combined blockade of ACE and AT1 receptors on Ang-(1-7) Ang-(1-7) contributes to antihypertensive effects of ACE inhibitors and ARBs ACE inhibition increases vasodilation by a bradykinin mechanism in response to flow-mediated dilation Effect of ACE inhibition on FMD in patients with CHF Bradykinin contributes to ACE inhibitor antihypertensive effects Regression of LVH with ACE inhibitors (rat model): Role of bradykinin Bradykinin and antihypertrophic effects of ACE inhibition: Evidence from a canine direct shock model Reduction in infarct size with ACE inhibition: Involvement of bradykinin Comparative effects of ACE inhibition and AT1 receptor blockade on fibrinolytic balance Role of bradykinin in risk reduction: Implications for clinical practice


Related at vwbg.org

Vascular Biology in Clinical Practice © Vol. 2, No. 1

Bradykinin and angiotensin-(1-7): Emerging allies in vascular functioning

This monograph Bradykinin and Angiotensin-(1-7): Emerging allies in vascular functioning is offered as part of a series of continuing medical education programs from the University of Florida College of Medicine.

Core Curriculum

Insulin Resistance and Cardiovascular Disease: New Perspectives From Vascular Biology

View/Download individual slides (94 Slides)

Core Curriculum

The Renin-Angiotensin-Aldosterone System: Linking New Data and Mechanisms for Cardiovascular Risk Reduction

View/Download individual slides (93 Slides)
More related